Ionis Pharmaceuticals

Yahoo Finance • 2 days ago

Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals

Company Logo Key opportunities in the oligonucleotide market include advancing therapeutics for rare and diverse diseases like neurodegenerative disorders and cancer, improving drug delivery systems, leveraging regulatory designations, an... Full story

Yahoo Finance • 5 days ago

Nike downgraded, IBM initiated: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Mizuho upgraded Shake Shack(SHAK) to O... Full story

Yahoo Finance • 16 days ago

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patientsHigh Dose SPINRAZA will be available... Full story

Yahoo Finance • 18 days ago

Cathie Wood Chooses Medical AI Over Mark Zuckerberg: Ark Loads Up On TEM Stock, Dumps Meta Shares

On Wednesday, Cathie Wood-led Ark Invest made significant trades, notably involving Tempus AI Inc and Meta Platforms Inc. These trades reflect Ark’s strategic adjustments amidst evolving market conditions and company-specific developments.... Full story

Yahoo Finance • 19 days ago

GSK: European Medicines Agency To Review MAA For Bepirovirsen

(RTTNews) - GSK plc (GSK, GSK.L) announced that the European Medicines Agency has accepted for review the marketing authorisation application for the use of bepirovirsen, an investigational antisense oligonucleotide, in the treatment of ad... Full story

Yahoo Finance • 20 days ago

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

Wave Life Sciences(NASDAQ:WVE), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.... Full story

Yahoo Finance • 20 days ago

Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106

Quick Read Ionis Pharmaceuticals (IONS) trades at $72.70 with Barclays raising its price target to $106, citing a projected $4 billion peak sales opportunity for olezarsen in severe hypertriglyceridemia with a June 30, 2026 PDUFA date, wh... Full story

Yahoo Finance • 23 days ago

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

– PDUFA date set for September 22, 2026 – CARLSBAD, Calif., March 23, 2026--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the... Full story

Yahoo Finance • 26 days ago

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone... Full story

Yahoo Finance • 26 days ago

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

On February 17, 2026, Boone Capital Management disclosed a new position in Tyra Biosciences(NASDAQ:TYRA), acquiring 398,482 shares worth $10.48 million at quarter’s end. What happened According to a Securities and Exchange Commission (SE... Full story

Yahoo Finance • 28 days ago

Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best growth stocks to buy according to billionaires. As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street. Based on 21 anal... Full story

Yahoo Finance • last month

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?

What happened According to a U.S. Securities and Exchange Commission (SEC) filing dated February 17, 2026, Boone Capital Management established a new position in HealthEquity by purchasing 212,856 shares. The reported value of the transac... Full story

Yahoo Finance • 2 months ago

Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance

Ionis Pharmaceuticals logo Key Points Olezarsen sNDA was accepted with priority review and a June 30 PDUFA date, and CEO Brett Monia said Ionis is positioned to launch "end of June, early July" with commercial supply and a ~200‑rep U.S.... Full story

Yahoo Finance • 2 months ago

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe high-dose regimen of nusinersen also slowed n... Full story

Yahoo Finance • 2 months ago

Tweedy Browne's Strategic Moves: Significant Increase in CNH Industrial NV

This article first appeared on GuruFocus. Insight into Tweedy Browne (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Warning! GuruFocus has detected 5 Warning Sign with IONS. Is IONS fairly valued? Test your thesis with our free DCF... Full story

Yahoo Finance • 2 months ago

What a $20 Million Bet on a Stock Down 3% Signals for Investors

On February 2, Tweedy, Browne disclosed a new position in UniFirst(NYSE:UNF), acquiring 102,059 shares during the fourth quarter in an estimated $19.69 million trade based on quarterly average pricing. What happened According to a SEC fi... Full story

Yahoo Finance • 2 months ago

Autoliv Stock Is Up 32% in a Year, But One Fund Just Cut $3.8 Million

On February 2, Tweedy, Browne Co disclosed in an SEC filing that it sold 31,740 shares of Autoliv(NYSE:ALV), an estimated $3.79 million trade based on quarterly average pricing. What happened In an SEC filing dated February 2, Connecticu... Full story

Yahoo Finance • 4 months ago

Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting holdings in... Full story

Yahoo Finance • 4 months ago

Ionis gets FDA breakthrough therapy status for zilganersen

[Neuron system disease] koto_feja/E+ via Getty Images * Ionis Pharmaceuticals (IONS [https://seekingalpha.com/symbol/IONS]) has received breakthrough therapy designation from the U.S. FDA for its drug zilganersen, aimed at treating Alex... Full story

Yahoo Finance • 5 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such a... Full story